Showing results (2301-2310 of 2,317) with videos related to
Sort By:
Pageof 232
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.Nature Medicine|January 8, 2024
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trialZefei Jiang, Quchang Ouyang, Tao Sun, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 TrialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.Frontiers in Oncology|October 12, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung AdenocarcinomaLong-Hua Guo, Ming-Feng Zhang, He-Long Zhang, et al.Nature Communications|March 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trialYang Sun, Hongying Yang, Jing Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.Pageof 232